Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
33.40
-0.11 (-0.33%)
At close: Mar 23, 2026, 4:00 PM EDT
33.40
0.00 (0.00%)
After-hours: Mar 23, 2026, 5:39 PM EDT
Stoke Therapeutics Employees
Stoke Therapeutics had 170 employees as of December 31, 2025. The number of employees increased by 42 or 32.81% compared to the previous year.
Employees
170
Change (1Y)
42
Growth (1Y)
32.81%
Revenue / Employee
$1,084,824
Profits / Employee
-$40,500
Market Cap
1.98B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 170 | 42 | 32.81% |
| Dec 31, 2024 | 128 | 18 | 16.36% |
| Dec 31, 2023 | 110 | -7 | -5.98% |
| Dec 31, 2022 | 117 | 15 | 14.71% |
| Dec 31, 2021 | 102 | 23 | 29.11% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| Ultragenyx Pharmaceutical | 1,371 |
| Adaptive Biotechnologies | 624 |
| Galapagos NV | 558 |
| Celldex Therapeutics | 198 |
| Aurinia Pharmaceuticals | 128 |
| Tyra Biosciences | 87 |
| Mesoblast | 81 |
STOK News
- 6 days ago - Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
- 19 days ago - The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome - Business Wire
- 27 days ago - Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - Business Wire
- 5 weeks ago - Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA) - Business Wire
- 6 weeks ago - Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - Business Wire
- 7 weeks ago - Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA - PRNewsWire
- 2 months ago - Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's Opportunity - Seeking Alpha
- 2 months ago - Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome - Business Wire